CD8A and breast cancer: In conclusion, this is the first study undertaken to evaluate the prognostic value of the CD3+ IM, CD8+ IM CD3+ CT, CD8+ CT, and ISCR in BC in the neoadjuvant setting, highlighting not only the prognostic value of this procedure, but also its potential benefit in researching TME cell subsets and their spatial distribution.